Tamer Othman

Tamer Othman

Auto-generated profile, based on publicly available information

Tamer Othman

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2022 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
TOTamer Othman
Tamer Othman
JPJuan Penaloza
Juan Penaloza
SZShiliang Zhang
Shiliang Zhang
CDClaire E. Daniel
Claire E. Daniel
DGDaria Gaut
Daria Gaut
JTJoseph Tuscano
Joseph Tuscano

5 March 2026 in Blood
Verified
Journal Article
Closed access
SDSanjal H. Desai
Sanjal H. Desai
AMAlison J. Moskowitz
Alison J. Moskowitz
RMReid W. Merryman
Reid W. Merryman
HSHarsh Shah
Harsh Shah
LPLevi D. Pederson
Levi D. Pederson
MMMatthew Mei
Matthew Mei
Combination therapy incorporating programmed cell death protein 1 (PD-1) blockade results in unprecedented response rates in both frontline and relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). Previous retrospective studies have suggested benefit for PD-1 blockade before autologous stem cell transplant (ASCT) but included few patients receiving PD-1 blockade with cytotoxic chemotherapy. To explore the impact of anti–PD-1 based salvage on outcomes for patients with R/R cHL, we retrospectively reviewed 1280 patients with R/R cHL who underwent ASCT from 2010 to 2022 at 6 transplant centers, none of whom received PD-1 blockade as part of frontline therapy. Overall, 25% received a PD-1 inhibitor at any point before ASCT (10% in conjunction with chemotherapy), 28% received salvage brentuximab vedotin (BV) without PD-1 blockade, and the rest received salvage chemotherapy alone. Patients who received PD-1 inhibitors at any point before ASCT had a significantly higher 2-year progression-free survival than those who received BV without PD-1 inhibitors or patients receiving chemotherapy alone (88.2%, 70.2%, and 67.4%, respectively; P< .0001). When restricted to patients in complete response before ASCT, the benefit of PD-1 blockade remained significant. PD-1 blockade before ASCT is independently associated with superior post-ASCT outcomes and patients proceeding to ASCT should be treated with PD-1–based salvage.

25 September 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
ZRZaid Abdel Rahman
Zaid Abdel Rahman
TOTamer Othman
Tamer Othman
RSRima M. Saliba
Rima M. Saliba
YVYenny Alejandra Moreno Vanegas
Yenny Alejandra Moreno Vanegas
RMRazan Mohty
Razan Mohty
PKPartow Kebriaei
Partow Kebriaei
Philadelphia-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subset of B-cell ALL with a poor prognosis with conventional therapies. Diagnostic challenges and lack of standardized treatment protocols contribute to suboptimal outcomes. Additionally, while allogeneic hematopoietic cell transplantation (HCT) is frequently recommended in adults with Ph-like ALL given its high-risk nature, data supporting its role remains limited. We conducted a multicenter retrospective study evaluating outcomes of adult patients undergoing HCT in first complete remission (CR1) for Ph-like ALL compared to Philadelphia chromosome positive ALL (Ph-pos) and other B-cell Philadelphia negative (Ph-neg) ALL. Data was collected from five academic centers across the US, focusing on HCT outcomes for patients with ALL. Patients undergoing HCT in CR1 between 2006 and 2021 were included. Among 673 patients, 83 (12.3%) had Ph-like ALL, while 271 (40.3%) had Ph-pos and 319 (47.4%) had Ph-neg ALL. Outcomes following HCT in CR1 for Ph-like ALL were comparable to Ph-neg ALL, with no significant differences in 3-year overall survival (66% vs. 59%, P = .1), progression-free survival (59% and 54%, P = .1), or relapse rates (22% vs. 20%, P = .7). In contrast, Ph-pos ALL had superior outcomes; 3-year OS (75%, P < .001), PFS (70%, P = .001) and relapse (12%, P = .003), this is likely attributed to tyrosine kinase inhibitor therapy. Our study suggests that HCT, coupled with effective 2nd line therapies can possibly mitigate the poor prognosis associated with Ph-like ALL and offers promising outcomes for patients with Ph-like ALL.

29 May 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
TOTamer Othman
Tamer Othman
PKPaul Koller
Paul Koller
HPHoda Pourhassan
Hoda Pourhassan
VAVaibhav Agrawal
Vaibhav Agrawal
DNDat Ngo
Dat Ngo
Ibrahim AldossIbrahim Aldoss
Ibrahim Aldoss

28 May 2024 in American Journal of Hematology
Verified
Journal Article
Closed access
TOTamer Othman
Tamer Othman
PKPaul Koller
Paul Koller
NTNi‐Chun Tsai
Ni‐Chun Tsai
DYDongyun Yang
Dongyun Yang
HPHoda Pourhassan
Hoda Pourhassan
MMMatthew Mei
Matthew Mei